Indeed, one of the first successful and well established targeted therapies which utilised this synthetic lethal approach in tumour cells was utilising PARP inhibitors, such as olaparib, in BRCA1/2-deficient breast and ovarian cancers that are unable to efficiently perform HR [67,68]. The gene discussed is PARP1; the disease is neoplasm.